Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Study of MD-7246 Administered Orally for 12 Weeks to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome

NCT03931785 is registered in ClinicalTrials.gov with Ironwood Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03931785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03931785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Study of MD-7246 Administered Orally for 12 Weeks to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 1, 2019
Completion date
March 11, 2020
Enrollment
515 (actual)
Sites
80

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome with diarrhea (ibs-d)